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An integrated national scale SARS-CoV-2 genomic 
surveillance network
The Coronavirus Disease 2019 (COVID-19) Genomics UK 
Consortium (COG-UK) was launched in March, 2020, with 
£20 million support from UK Research and Innovation, the 
UK Department of Health and Social Care, and Wellcome 
Trust. The goal of this consortium is to sequence severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
for up to 230 000 patients, health-care workers, and other 
essential workers in the UK with COVID-19, which will 
help to enable the tracking of SARS-CoV-2 transmission, 
identify viral mutations, and integrate with health data to 
assess how the viral genome interacts with cofactors and 
consequences of COVID-19. 
Results from this initiative are guiding decision 
makers, including the weekly reports to the UK Scientific 
Advisory Group for Emergencies (SAGE). This initiative 
is the first time that large-scale genomic epidemiology 
has been used to guide and inform the public health 
response to a pandemic in the UK, setting the stage for 
genomics to serve as a core tool for outbreak tracking in 
future pandemics.
COG-UK builds on the UK’s strengths in pathogen 
genomics, population health sciences, and health 
informatics. It benefits from a large and well equipped 
network of specialist academic and research facilities 
working in close collaboration with the UK’s public 
health agencies and the National Health Service (NHS). 
Partners in COG-UK at the time of writing are shown in 
the appendix (p 4). As COG-UK’s example could help to 
inform other countries seeking to rapidly develop and 
scale-up national sequencing capacity and a joined-up 
health information system, we describe six key features 
of our experience. 
COG-UK is co-ordinated from an integrated hub (based 
between the University of Cambridge [Cambridge, UK] 
and Wellcome Sanger Institute [Cambridge, UK]), with 
sample collection and sequencing taking place at multiple 
organisations across the country. This decentralised model 
enables rapid sequencing and prioritisation at the point 
of need, while supporting equitable national access. The 
core of COG-UK is formed around a network of regional 
sequencing centres in UK academic institutions and UK 
public health agencies. Sequencing in regional sequencing 
centres is close to real time, with a 24–48 h turnaround 
time, with data interpreted and used locally. In addition, 
the Wellcome Sanger Institute provides a high volume 
national sequencing capacity using high throughput, 
cost efficient viral sequencing for UK hospitals that do not 
have sequencing capabilities (ie, contributing partners), 
the national testing centres for key workers, and overspill 
from the regional sequencing centres. 
To help prioritise finite sequencing resources, COG-
UK has developed a sampling strategy to concurrently 
enable broad population-level analyses, targeted 
analyses of specific populations, and freedom to tackle 
local priorities. This strategy aims to maximise insight 
while minimising demands on stretched local facilities. 
To maximise speed and inclusiveness, COG-UK adopts 
a range of technical approaches (ie, amplicons, baits, and 
metagenomics) and technologies (ie, single molecule 
vs next generation sequencing approaches), enabling 
centres to build on existing pipelines and expertise. 
Several centres have adopted a tiling amplicon sequencing 
approach developed by the ARTIC network, which is 
run on multiple platforms to help achieve the very high 
sample throughput required. Tight linkage to diagnostic 
and public health laboratories minimises transport and 
analysis delays. The system needs to be continuous and 
rapid, with a target of 48 h from sample collection to 
analysis. 
Sequence data are uploaded to the Cloud Infra-
structure for Microbial Bioinformatics (MRC-CLIMB) 
server;1 a centralised, replicated environment for data 
storage and analysis. MRC-CLIMB provides a ready-made 
starting point for the computational analysis, with the 
option to integrate with other resources within the 
UK or scale into the commercial cloud. A standardised 
lineage assignment to enable national and international 
comparison has been developed,2 which are linked to 
data and released interactively via Microreact.3 Sequence 
data are made open access through release into the 
European Nucleotide Archive through the European 
Bioinformatics Institute and the Global Initiative on 
Sharing All Influenza Data. 
To enhance the value of sequence data, we are 
creating an integrated dataset connecting viral genome 
data with multidimensional patient data from clinical, 
For more on COG-UK see https://
www.cogconsortium.uk
For more on the ARTIC network 
see https://artic.network
For more on European 
Bioinformatics Institute see 
https://www.ebi.ac.uk/ena
For more on the Global 
Initiative on Sharing All 
Influenza Data see https://www.
gisaid.org
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epidemiological, and other sources. By accessing 
existing NHS e-health records and related sources, the 
goal is to avoid adding to the burden on busy NHS staff. 
Each week a sequence data cutoff is applied 
across the consortium to give a defined dataset for 
weekly analysis to report to SAGE, initially focusing 
on: (1) local transmission versus imported cases,4 
(2) rates of epidemic growth,5,6 (3) reconstructing spatial 
movement, (4) chains of transmission,7 (5) observed 
genetic changes, and (6) identification of genomic 
changes potentially affecting common diagnostic tests 
or direct (eg, chemotherapeutics) or indirect therapies.
Our website will provide a publication strategy, 
including open access publications, bespoke local and 
regional analyses, and data summaries suitable for the 
general public. 
In only 4 weeks, over 7000 genomes have been 
sequenced by COG-UK, the largest number of any 
country to date. We are committed to open and 
global collaboration. Reciprocity is crucial to genomic 
epidemiological approaches; the use of our data will be 
maximised if other countries adopt similar approaches. 
See Online for appendix
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